Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2021-12-31 |
2021-01-01 to 2021-12-31 |
As at 2020-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification | — |
GenSight Biologics S.A
|
— |
| Domicile of entity | — |
74, rue du Faubourg Saint-Antoine – 75012 Paris
|
— |
| Legal form of entity | — |
société anonyme
|
— |
| Principal place of business | — |
France
|
— |
| Description of nature of entity's operations and principal activities | — |
We are an innovative clinical-stage gene therapy company with an initial focus on discovering, developing and commercializing novel therapies for severe retinal neurodegenerative diseases.
|
— |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current trade receivables |
754,000
EUR
|
— |
52,000
EUR
|
| Current trade payables |
11,561,000
EUR
|
— |
7,588,000
EUR
|